GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France

About this update from Gensight Biologics Sa

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/8f03ec93ac04e2dd0c31a8f748cc1ccb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7NIV8M3Y9jZiHHkFTTq7BQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8f03ec93ac04e2dd0c31a8f748cc1ccb","width":480,"height":204}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"French medicines agency ANSM has granted authorization for named patient early access program for GS010/LUMEVOQ®, a gene therapy indicated for the treatment of ND4-LHON.","length":169,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":169,"olType":false},{"type":"text","content":"PARIS, December 22, 2025--(BUSINESS WIRE)--Regulatory News:","length":59,"tagName":"p"},{"type":"text","content":"GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the French medicines safety agency ANSM (Agence nationale de sécurité du médicament et des produits de santé) has granted compassionate use authorization (Autorisation d’Accès Compassionnel, or AAC) for the use of the GS010/LUMEVOQ® gene therapy1.","length":509,"tagName":"p"},{"type":"text","content":"The AAC Program in France is a national scheme that enables patients suffering from serious, rare or disabling diseases to benefit from a treatment that does not have marketing authorization, when there are an unmet medical need and no appropriate therapy. To be eligible for an AAC program, the candidate treatment must present a favorable benefit-risk ratio. Requests for AAC may be initiated only by healthcare professionals, who submit named patient requests to the ANSM, which then evaluates and authorizes the access requests. Patients for whom applications for treatment with GS010 are submitted must meet specific eligibility criteria, including the length of time since the onset of their vision loss.","length":710,"tagName":"p"},{"type":"text","content":"About Leber Hereditary Optic Neuropathy (LHON)","length":46,"tagName":"p"},{"type"...

More updates from Gensight Biologics Sa